Inferno: what the name hides and what the composition shows

A woman lacing her shoes on warm stone steps before a morning walk

Inferno is a named combination of AOD-9604, CJC-1295, ipamorelin, and MOTS-C. The grouping mixes a growth hormone fragment studied in obesity trials, two growth hormone releasing approaches, and a mitochondrial peptide. No study of the combination was identified.

Composition

  • aod-9604
  • cjc-1295
  • ipamorelin
  • mots-c

Overview

This grouping is marketed around fat metabolism. The most relevant fact is that its most directly metabolic component, AOD-9604, was studied in human obesity trials and did not become an approved therapy. That outcome is part of the evidence and belongs on the page as prominently as any mechanistic rationale.

Why these are grouped

The rationale offered is that a growth hormone fragment associated with fat metabolism, two pathways of growth hormone release, and a mitochondrial signalling peptide address energy handling from several angles. No published work tested whether those angles combine usefully.

What each ingredient contributes

aod-9604

A fragment of the growth hormone molecule studied in human obesity trials. Those trials are part of the record precisely because they did not produce an approved product.

cjc-1295

A releasing hormone analogue included for growth hormone axis activity, with limited human data.

ipamorelin

A secretagogue acting at a different receptor, included for pathway breadth.

mots-c

A mitochondrial-derived peptide from animal metabolic research, with minimal human data.

Combination evidence

  • No published or registered study of the Inferno combination was identified.
  • No safety data describe these four substances used together.
  • The absence of combination evidence is the central finding of this page.

AOD-9604 has real human trial exposure in obesity research that did not establish it as an effective therapy. CJC-1295 has small human pharmacology studies. Ipamorelin and MOTS-C are supported by preclinical work. None of that describes the combination, and a component that failed to demonstrate benefit alone does not become effective by being grouped with others.

Preclinical rationale

  • The fat-metabolism region of the growth hormone molecule is the design basis for AOD-9604.
  • Two receptor pathways converge on pituitary growth hormone release.
  • Mitochondrial-derived peptides appear in animal models of energy metabolism.

What is not established

  • Any effect of the combination on body weight, fat mass, or metabolic markers in humans.
  • Whether AOD-9604 performs differently in combination than it did alone in trials.
  • Long-term safety of the grouping.
  • Interaction with established weight management medicines.

Questions to discuss with a physician

  • What happened when the most metabolic component here was tested alone in people?
  • Is there a better-evidenced option for my goal?
  • How would this interact with what I already take?
  • What would you monitor, and what would end the trial of it?
  • What results should I not expect?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.